We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





LumiraDx to Present on Impact of Its Next-Generation Microfluidic Technology at AACC 2022

By LabMedica International staff writers
Posted on 20 Jul 2022
Print article
Image: Fast Lab Solutions enable laboratories to improve throughput (Photo courtesy of LumiraDx)
Image: Fast Lab Solutions enable laboratories to improve throughput (Photo courtesy of LumiraDx)

LumiraDx (London, UK) will be hosting an industry workshop at the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo that will include data-backed insights on the impact of the company’s advanced microfluidic technology over lateral flow point-of-care antigen tests, and the role of these rapid immunoassays in response to the COVID-19 pandemic.

Speaking during the session will be lead author on a number of research papers reviewing the SARS-CoV-2 Ag test, Paul Drain, MD, MPH, FIDSA, Associate Professor in the Departments of Global Health, Medicine (Infectious Diseases), and Epidemiology at the University of Washington, along with Brian DuChateau, Ph.D., D (ABMLI), VP of Clinical and Scientific Affairs, LumiraDx. Key findings in the study revealed that the LumiraDx SARS-CoV-2 Ag test showed a 97.6% positive agreement to RT PCR in patients up to 12 days following symptom onset, and 100% PPA up to Ct 33.

In addition to hosting the workshop, LumiraDx will be exhibiting in the show’s main exhibition hall at booth #4821, and will be presenting its poster abstract ‘Correlation of the Rapid, Point-of-Care LumiraDx SARS-CoV-2 Antibody Test to Other SARS-CoV-2 Antibody Tests and to Viral Neutralization’ (poster B-195) and be featured in a poster abstract by John’s Hopkins Hospital ‘Implementation of POCT COVID-19 Testing Using a LumiraDx SARS-CoV-2 Testing Platform in Patient and Employee Testing Environments’ (poster A-142.)

“Studies have shown that point of care antigen tests with sufficient sensitivity and specificity can facilitate diagnosis, treatment, and mitigate reliance on slower, conventional laboratory-based testing and infrastructure,” said Dr. DuChateau. “However, the COVID-19 pandemic not only demonstrated the need for this type of testing, but also showed how quick result turn-around-time can mitigate rates of infection. LumiraDx’s actively controlled microfluidic testing technology brings lab-comparable performance to the point-of-need, supporting several unique use-cases during the pandemic and beyond.”
 

Related Links:
LumiraDx

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.